fat-1 Antibody

What is FAT1 and why is it important in cancer research?

FAT1 (FAT atypical cadherin 1) is a large transmembrane protein belonging to the cadherin superfamily. It has a molecular mass of 506.3 kDa and consists of 4588 amino acids with nuclear and membrane subcellular localization. FAT1 is expressed in many epithelial cells and some endothelial and smooth muscle cells .

FAT1 has gained significant attention in cancer research due to its context-dependent role as either a tumor suppressor or oncogene. Studies have shown that FAT1 is broadly expressed in primary and metastatic colorectal cancer (CRC) stages, with its presence at the plasma membrane of cancer cells contrasting with minimal detection in normal human samples . FAT1 is also implicated in T-cell acute lymphoblastic leukemia (T-ALL), with aberrant expression in approximately 53% of cases compared to absent expression in normal T-cells . Additionally, FAT1 overexpression in lung cancer correlates with unfavorable prognosis, suggesting its potential as both a biomarker and therapeutic target .

What specific applications are suitable for FAT1 antibodies in laboratory research?

FAT1 antibodies can be utilized in multiple experimental applications:

These applications collectively enable comprehensive investigation of FAT1 expression patterns, localization dynamics, and functional roles in normal and pathological contexts .

How can researchers differentiate between FAT1 expression in normal versus cancerous tissues?

Distinguishing FAT1 expression between normal and cancerous tissues is crucial for diagnostic applications. Research has established distinct expression patterns:

In normal tissues:

• FAT1 is marginally detected in normal human samples

• Expression is notably low or absent in normal colon samples

• Normal T-cells show negligible FAT1 expression

In cancer tissues:

• FAT1 shows abundant and homogeneous expression at the plasma membrane in CRC cells (39 out of 49 cases)

• FAT1 is detected in CRC regardless of mutations in KRAS and BRAF genes

• Approximately 53% of T-ALL patient samples are FAT1 positive, compared to only 16% positivity in early T-ALL samples

• FAT1 is overexpressed in lung cancer and associated with unfavorable prognosis

For analysis, researchers should implement semi-quantitative scoring systems for both percentage of positive cells and signal intensity. Cases can be categorized as low positive (10-33% positive cells), moderate positive (33-66%), or strong positive (>66%), with signal intensity graded from 0 (no positivity) to 3 (strong positivity) .

How does FAT1 expression correlate with stage and grade in colorectal cancer?

FAT1 expression in colorectal cancer demonstrates interesting correlations with tumor stage and differentiation:

• FAT1 is expressed across all CRC stages and grades but shows distinct patterns

• FAT1 was detected in both early (pT1 and pT2) and late (pT3 and pT4) CRCs with similar frequencies (intense/moderate staining in 54% and 49% of cases, respectively)

• pT1 CRC tends to be recognized with stronger intensity than more advanced stages (p-value: 0.03)

• Both poorly and well-differentiated CRCs express FAT1, though well-differentiated samples show higher frequency and stronger staining intensity (p-value: 0.02)

These findings suggest that while FAT1 is broadly expressed in CRC, its expression patterns may have prognostic significance, particularly in early-stage disease.

What is the relationship between FAT1 and WNT signaling in cancer development?

The relationship between FAT1 and WNT signaling varies by cancer type and represents a critical aspect of cancer biology:

In T-ALL:

• Genes correlating with FAT1 expression show enrichment in WNT signaling pathways, representing the most enriched single pathway

• FAT1 knockdown or knockout leads to downregulation of WNT pathway target genes (CCND1, MYC, LEF1)

• FAT1 overexpression confers a proliferative advantage, likely through WNT pathway activation

In CRC:

• FAT1 expression and localization does not significantly differ between CRC groups with high or low β-catenin activation

• CRC samples with low β-catenin activation (192 samples) and high β-catenin activation (97 samples) showed comparable FAT1 expression patterns

These findings suggest context-dependent interactions between FAT1 and WNT signaling across different cancer types, with potential implications for targeted therapeutic approaches.

How does epigenetic regulation impact FAT1 expression in T-ALL?

Epigenetic mechanisms play a crucial role in regulating FAT1 expression in T-ALL:

• Aberrant expression of FAT1 is strongly associated with FAT1 promotor hypomethylation in most T-ALL cases

• A specific subset of T-ALL patient samples, mainly consisting of TLX1-driven cases, exhibits methylation-independent high FAT1 expression

• This suggests multiple regulatory mechanisms control FAT1 expression in T-ALL:

  • Promoter methylation status (primary mechanism)

  • TLX1-dependent transcriptional regulation (alternative mechanism)

These findings have implications for understanding T-ALL pathogenesis and potentially developing epigenetic therapies targeting FAT1 expression.

What technical considerations are essential when using FAT1 antibodies for Western blot analysis?

Successfully detecting FAT1 via Western blot requires specific technical adaptations due to its large size and structural properties:

Researchers should also consider extended transfer times, optimized blocking conditions, and sensitive detection systems for reliable visualization of this high molecular weight protein.

How should immunohistochemistry protocols be optimized for FAT1 detection in tissue samples?

Optimizing immunohistochemistry (IHC) for FAT1 detection requires careful protocol adjustment:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues have been successfully used for FAT1 detection

  • Effective antigen retrieval is critical as FAT1 epitopes may be masked during fixation

• Antibody parameters:

  • Working dilutions typically range from 1:10 to 1:500

  • Extended incubation times (overnight at 4°C) often improve signal specificity

• Scoring methodology:

  • Implement semi-quantitative assessment for both percentage and intensity

  • Score membrane and cytoplasmic localization separately

  • Consider dual staining with β-catenin for correlation studies

• Essential controls:

  • Include normal tissue controls from the same patient when possible

  • Use irrelevant isotype control antibody and/or omit primary antibody as negative controls

This optimized approach enables reliable detection and accurate quantification of FAT1 expression in clinical samples.

What strategies are effective for FAT1 knockdown/knockout to study its functional roles?

Multiple complementary approaches can be employed to modulate FAT1 expression for functional studies:

Research has demonstrated that FAT1 knockdown or knockout leads to impaired proliferation and downregulation of WNT pathway target genes in T-ALL models . Similarly, suppression of FAT1 in lung cancer cells results in reduced cell proliferation, migration, and invasion . These functional outcomes provide important validation metrics for successful FAT1 modulation.

How can researchers address the challenges of working with such a large protein in experimental settings?

Working with the 506.3 kDa FAT1 protein presents unique technical challenges that require specific solutions:

These adaptations significantly improve experimental reliability when working with FAT1 protein.

What approaches are recommended for validating FAT1 antibody specificity?

Comprehensive validation of FAT1 antibody specificity is essential for generating reliable research data:

• Genetic validation:

  • Test antibodies in FAT1 knockdown/knockout systems

  • Utilize overexpression of tagged FAT1 constructs

  • Express domain-specific constructs to map epitope recognition

• Technical validation:

  • Test across multiple applications (WB, IHC, IF) to confirm consistent detection patterns

  • Perform peptide competition assays to verify epitope-specific binding

  • Consider mass spectrometry identification of immunoprecipitated proteins

• Cross-species validation:

  • Test antibodies against orthologs in relevant model organisms

  • Consider sequence homology when interpreting cross-species results (e.g., the cytoplasmic domain of drosophila Fat shows sequence identity with mammalian FAT1)

These systematic validation approaches ensure that experimental findings accurately reflect FAT1 biology rather than potential artifacts.

How can FAT1 antibodies be evaluated for potential therapeutic applications?

Evaluation of FAT1 antibodies for therapeutic applications requires rigorous assessment beyond research applications:

• Target validation studies:

  • Confirm FAT1 expression in target tissues using clinically validated IHC protocols

  • Assess differential expression between normal and tumor tissues

  • Studies show FAT1 accumulates at the plasma membrane of cancer cells while being marginally detected in normal samples

• Antibody characterization:

  • Evaluate epitope accessibility in intact cells using flow cytometry

  • Assess internalization capabilities, as demonstrated with mAb198.3 in CRC

  • Determine specificity for cancer vs. normal cells

• Functional evaluation:

  • Measure direct anti-tumor effects (growth inhibition, apoptosis induction)

  • Assess antibody-dependent cellular cytotoxicity (ADCC) potential

  • Research shows mAb198.3 reduces cancer growth in colon cancer xenograft models

• Translational potential:

  • Develop humanized versions to reduce immunogenicity

  • Explore antibody-drug conjugate (ADC) approaches

  • Consider combination strategies with standard therapies

These evaluation steps are critical for advancing FAT1 antibodies from research tools to therapeutic agents.

How might FAT1 antibodies be developed for cancer-specific therapeutic applications?

The development of FAT1-targeted therapeutics represents an emerging opportunity based on several promising research findings:

• Target validation evidence:

  • FAT1 is broadly expressed in primary and metastatic CRC stages regardless of KRAS and BRAF mutations

  • FAT1 overexpression in lung cancer correlates with unfavorable prognosis

  • FAT1 is expressed in 53% of T-ALL patient samples compared to absent expression in normal T-cells

• Therapeutic strategies:

  • Naked antibodies: Direct targeting of FAT1-expressing cancer cells

  • Antibody-drug conjugates: Utilizing efficient internalization demonstrated with mAb198.3

  • Bispecific antibodies: Engaging immune effector cells with FAT1-expressing tumors

• Addressing resistance mechanisms:

  • FAT1-targeted approaches may be effective against tumors resistant to current EGFR-targeted therapies

  • Combination strategies with standard chemotherapeutics or targeted agents

• Biomarker development:

  • FAT1 expression as a companion diagnostic

  • Correlation with specific genetic alterations or cancer subtypes

These approaches could expand therapeutic options for patients with limited treatment alternatives, particularly those with KRAS/BRAF mutations resistant to current targeted therapies.

What research questions remain unexplored regarding FAT1's role in cancer biology?

Despite significant advances, several critical questions about FAT1 biology remain to be addressed:

• Context-dependent functions:

  • Mechanisms determining FAT1's role as tumor suppressor versus oncogene

  • Tissue-specific interaction partners that modulate FAT1 function

  • Relationship between FAT1 mutations versus expression changes in different cancer types

• Signaling mechanisms:

  • Complete mapping of FAT1 interaction with WNT signaling components

  • Cross-talk between FAT1 and other cancer-relevant pathways

  • Impact of post-translational modifications on FAT1 signaling

• Clinical relevance:

  • Prognostic value of FAT1 expression patterns in diverse cancer types

  • Predictive biomarker potential for response to specific therapies

  • Correlation between FAT1 status and immune infiltration in tumors

• Evolutionary perspectives:

  • Comparative analysis of FAT1 function across species

  • Evolutionary pressure on FAT1 structural domains

Addressing these questions will further illuminate FAT1's complex role in cancer and potentially reveal new therapeutic opportunities.